Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHARM > Surfactants > Flashcards

Surfactants Flashcards

1
Q

Hazards and Complications

Airway Occlusion, Desaturation, and \_\_\_\_\_\_?
High aterial (PaO2) values
Overventilation and hypocarbia
Apnea
Pulmonary Hemorage
A

bradycardia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Hazards and complications

Airway occlusion, \_\_\_\_\_\_\_, and bradycardia
High arterial valules (PaO2)
overventilation and hypocardbia
apnea
pulmonary hemorrhage
A

Desaturation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Hazards and Complications

Airway occlusion, desaturation, bradycardia 
High arterial values (PaO2)
Overventilation and \_\_\_\_\_\_\_?
apnea
pulmonary hemorrhage
A

Hypocarbia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Hazards and Complications

Airway occlusion, Desaturation, bradycardia 
High \_\_\_\_\_ values (\_\_\_\_)
overventilation and hypocarbia
apnea
pulmonary hemorrhage
A

Arterial; PaO2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Hazards and Complications

Airway occlusion, desaturation, bradycardia
high arterial (PaO2) values
Overventilation and hypocarbia 
Apnea
\_\_\_\_\_\_\_\_\_\_?
A

Pulmonary Hemorrhage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Beractant trade name

A

Survanta

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Beractant

Prophylactic therapy of premature infants less
than 1250 g birth weight or with evidence of
_________ and risk of RDS; the agent
should be given within 15 minutes of birth or as
soon as possible

A

surfactant deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Beractant

Prophylactic therapy of premature infants less
than 1250 g birth weight or with evidence of
surfactant deficiency and risk of RDS; the agent
should be given within ?

A

15 minutes of birth or as

soon as possible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Beractant

Prophylactic therapy of premature infants less
than _____ birth weight or with evidence of
surfactant deficiency and risk of RDS; the agent
should be given within 15 minutes of birth or as
soon as possible

A

1250 g

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Beractant

Prophylactic therapy of premature infants less
than 1250 g birth weight or with evidence of
surfactant deficiency and risk of _____; the agent
should be given within 15 minutes of birth or as
soon as possible

A

RDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Beractant (Survanta)
◦ A modified natural surfactant (bovine)
◦ Indications for use

_______ therapy of premature infants less
than 1250 g birth weight or with evidence of
surfactant deficiency and risk of RDS; the agent
should be giv within 15 minutes of birth or as
soon as possible

A

Prophylactic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Beractant (Survanta)
◦ A modified natural surfactant (bovine)
◦ Indications for use

______ treatment of infants with evidence of
RDS; the agent should be given within 8 hours
of age

A

Rescue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Beractant (Survanta)
◦ A modified natural surfactant (bovine)
◦ Indications for use

Rescue treatment of infants with evidence of
_____ the agent should be given within 8 hours
of age

A

RDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Beractant (Survanta)
◦ A modified natural surfactant (bovine)
◦ Indications for use

Rescue treatment of infants with evidence of
RDS; the agent should be given within _____
of age

A

8 Hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Beractant (Survanta)

Administration
Do not shake; let stand at room temperature for
20 minutes; given in quarters from a syringe
and instilled into the trachea through a ______ catheter placed into the endotracheal
tube (ETT)

A

5-French

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Calfactant (Infasurf)
◦ A modified natural surfactant (bovine)
◦ Indications for use

The prevention (prophylaxis) of RDS in
premature infants less than ___ weeks of
gestational age and at high risk for RDS

17
Q

Calfactant (Infasurf)
◦ A modified natural surfactant (bovine)
◦ Indications for use

The prevention (prophylaxis) of RDS in
premature infants less than 29 weeks of
gestational age and at high risk for ____

18
Q

Calfactant (Infasurf)
◦ A modified natural surfactant (bovine)
◦ Indications for use

 The treatment (\_\_\_\_\_) of premature infants less 
than or equal to 72 hours of age who develop 
RDS and require endotracheal intubation
19
Q

Calfactant (Infasurf)
◦ A modified natural surfactant (bovine)
◦ Indications for use

 The treatment (rescue) of premature infants less 
than or equal to \_\_\_ hours of age who develop 
RDS and require endotracheal intubation
20
Q

Calfactant (Infasurf)
◦ A modified natural surfactant (bovine)
◦ Indications for use

The treatment (rescue) of premature infants less
than or equal to 72 hours of age who develop
_____ and require _______ ________?

A

RDS; Endotracheal Intubation

21
Q

Calfactant (Infasurf)
◦ A modified natural surfactant (bovine)
◦ Administration

___-____ _______
Catheter administration

A

Side-port adaptor

22
Q

Calfactant (Infasurf)
◦ A modified natural surfactant (bovine)
◦ Administration

Side-port adaptor
_____ ________

A

Catheter administration

23
Q

Poractant Alfa (Curosurf)
◦ Natural surfactant (_____)
◦ Indications for use

For the treatment (rescue) of premature infants
with RDS, reducing mortality and
pneumothoraces

24
Q

Poractant Alfa Trade name

25
Q

Poractant Alfa (Curosurf)
◦ Natural surfactant (porcine)
◦ Indications for use

For the treatment (rescue) of _____ _______
with RDS, reducing mortality and
pneumothoraces

A

premature infants

26
Q

Poractant Alfa (Curosurf)
◦ Natural surfactant (porcine)
◦ Indications for use

For the treatment (rescue) of premature infants
with RDS, reducing _____ and
pneumothoraces

27
Q

Poractant Alfa (Curosurf)
◦ Natural surfactant (porcine)
◦ Indications for use

For the treatment (rescue) of premature infants
with RDS, reducing mortality and
_________

A

pneumothoraces

28
Q

Poractant Alfa (Curosurf)
◦ Natural surfactant (porcine)
◦ Indications for use

Unlabeled uses: _____ _____ aspiration
syndrome in term infants; respiratory failure
caused by group B streptococcal infection in
neonates

A

severe meconium

29
Q

Poractant Alfa (Curosurf)
◦ Natural surfactant (porcine)
◦ Indications for use

Unlabeled uses: severe meconium aspiration
syndrome in term infants; respiratory failure
caused by _____ _ _____ infection in
neonates

A

group B streptococcal

30
Q

Poractant Alfa (Curosurf)
◦ Natural surfactant (porcine)
◦ Indications for use

Unlabeled uses: severe meconium aspiration
syndrome in term infants; respiratory failure
caused by group B streptococcal infection in
_____

31
Q

Poractant Alfa (Curosurf)
◦ Natural surfactant (porcine)
◦ Indications for use

_____ uses: severe meconium aspiration
syndrome in term infants; respiratory failure
caused by group B streptococcal infection in
neonates

32
Q

Poractant Alfa (Curosurf)
◦ Natural surfactant (porcine)
◦ Indications for use

◦ Administration
No need to _______
Administered in two aliquots

A

reconstitute

33
Q

Poractant Alfa (Curosurf)
◦ Natural surfactant (porcine)
◦ Indications for use

◦ Administration
No need to reconstitute
Administered in ____ aliquots

34
Q

Poractant Alfa (Curosurf)
◦ Natural surfactant (porcine)
◦ Indications for use

◦ Administration
No need to reconstitute
Administered in two _____

PHARM (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions